NuVasive (NASDAQ:NUVA) Downgraded to “Sell” at BidaskClub
NUVA has been the subject of a number of other research reports. ValuEngine lowered shares of USD Partners from a hold rating to a sell rating in a research note on Friday, June 14th. Zacks Investment Research lowered shares of Guaranty Federal Bancshares from a hold rating to a sell rating in a research note on Tuesday, April 23rd. BTIG Research lowered shares of EVO Payments from a buy rating to a neutral rating in a research note on Monday, July 1st. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $25.00 target price on shares of Menlo Therapeutics in a research note on Thursday, May 2nd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the stock. NuVasive currently has an average rating of Hold and a consensus target price of $66.79.
Shares of NUVA stock opened at $57.07 on Tuesday. The company has a market cap of $2.97 billion, a price-to-earnings ratio of 24.22, a PEG ratio of 2.10 and a beta of 1.11. The company’s fifty day simple moving average is $58.31. The company has a quick ratio of 1.96, a current ratio of 3.75 and a debt-to-equity ratio of 0.80. NuVasive has a 12 month low of $43.51 and a 12 month high of $72.41.
In other news, President Matthew Link sold 10,100 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $62.00, for a total value of $626,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.97% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of NUVA. Norges Bank bought a new position in NuVasive during the fourth quarter valued at about $50,996,000. American Century Companies Inc. bought a new position in NuVasive during the fourth quarter valued at about $6,258,000. Macquarie Group Ltd. grew its position in NuVasive by 17.7% during the fourth quarter. Macquarie Group Ltd. now owns 825,194 shares of the medical device company’s stock valued at $40,897,000 after buying an additional 124,224 shares during the period. Segall Bryant & Hamill LLC bought a new position in NuVasive during the fourth quarter valued at about $4,283,000. Finally, Hsbc Holdings PLC grew its position in NuVasive by 1,132.9% during the fourth quarter. Hsbc Holdings PLC now owns 85,084 shares of the medical device company’s stock valued at $4,210,000 after buying an additional 78,183 shares during the period.
NuVasive Company Profile
NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Recommended Story: Return On Assets
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.